Is CJC-1295 DAC FDA approved?

CJC-1295 DAC is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Hexarelin FDA approved?

Hexarelin is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CJC-1295 DAC administered in research settings?

In research settings, CJC-1295 DAC is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Hexarelin administered in research settings?

In research settings, Hexarelin is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 DAC vs Hexarelin

Peptide Comparison

CJC-1295 DAC vs Hexarelin

Name: CJC-1295 DAC vs Hexarelin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 DAC

CJC-1295 with DAC

Fat LossNot EvaluatedResearch Only

Half-life: 6–8 days

1 providers listed

Full CJC-1295 DAC profile →

Hexarelin

Examorelin

PerformanceNot EvaluatedResearch Only

Half-life: ~30-60 minutes

23 providers listed

Full Hexarelin profile →

Bottom line

CJC-1295 DAC has a longer half-life than Hexarelin, so it generally needs less frequent dosing.

Quick Verdict

CJC-1295 DAC

Half-life

6–8 days

Hexarelin

Half-life

~30-60 minutes

Which One Should You Choose?

Your goal	Better option
Less frequent dosing (longer half-life)	CJC-1295 DAC
More provider options (1 vs 23)	Hexarelin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 DAC

Hexarelin

Mechanism Family

GH / IGF Axis

Half-life

6–8 days

~30-60 minutes

FDA Status

not evaluated

Admin Routes

subcutaneous

Availability

Research Only

Providers

1 listed

23 listed

Avail. Notes

Long-acting GHRH analog with a Drug Affinity Complex (DAC) modification. No FDA approval. Not on the FDA 503A bulks list. WADA-prohibited as a growth hormone releasing factor. Sold as a research chemical only.

Potent hexapeptide GH secretagogue. No FDA approval anywhere. Not on FDA Category 1 or Category 2 list. WADA prohibited. More potent GH pulse than GHRP-6. Research use only.

Research Evidence

CJC-1295 DAC

RCT · 1 key study · dated evidence base — most recent 2006

Hexarelin

RCT · 1 key study · dated evidence base — most recent 2001

Research Citations

CJC-1295 DAC

RCT2006 · Journal of Clinical Endocrinology and Metabolism

Effects of a single injection of CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy…

Hexarelin

RCT2001 · Journal of Clinical Endocrinology and Metabolism

Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and inter…

About CJC-1295 DAC

CJC-1295 DAC is a GHRH analog carrying a Drug Affinity Complex (DAC) modification that binds covalently to circulating albumin, greatly extending its plasma half-life relative to unmodified or short-acting GHRH analogs. Through this albumin binding it acts as a long-lasting agonist at pituitary GHRH receptors, associated in research with sustained growth hormone and downstream IGF-1 elevation. This contrasts with the non-DAC form (Mod GRF 1-29), whose action is measured in minutes rather than days.

Research Areas

GH and IGF-1 elevation studied in a single-dose human PK trialsustained GHRH-receptor agonism via albumin bindingextended plasma half-life relative to short-acting GHRH analogsbody-composition and GH-axis research contextssubcutaneous administration in published research

About Hexarelin

Potent synthetic GHRP; strongest GH secretagogue in its class; also activates CD36 scavenger receptor for cardioprotective effects

Research Areas

potent GH secretion via GHS-R1a agonismcardiac tissue activity via CD36 receptor pathwaysmuscle recovery and lean mass supportreceptor desensitization with repeated use — cycling protocols studied

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 DAC

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Hexarelin

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

CJC-1295 DAC

$10.63/mg

$9.74 – $15.25 range

20 vendors

View price index →Find providers →

Hexarelin

$9.46/mg

$8.09 – $11.40 range

19 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 DAC

1 listed

Browse directory →

Providers offering

Hexarelin

23 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 DAC vs Hexarelin — Per-mg Price Comparison. Retrieved August 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295-dac/hexarelin

https://peptidebase.io/peptides/compare/cjc-1295-dac/hexarelin Methodology License Download JSON Download CSV